Drug Enforcement Administration
Skip Navigation

Press Room
News Releases
E-mail updates red envelope
Speeches & Testimony
Multi-Media Library

About Us
Mission
Leadership
History
Organizational Chart
Programs & Operations
Wall of Honor
DEA Museum
Office Locations

Careers at DEA

Drug Information

Law Enforcement
Most Wanted
Major Operations
Threat Assessment
Training Programs
Stats & Facts
Additional Resources

Drug Prevention
For Young Adults
Additional Resources

Diversion Control & Prescription Drugs
Registration
Cases Against Doctors

Drug Policy
Controlled Substances Act
Federal Trafficking Penalties
Drug Scheduling

Legislative Resources

Publications

Acquisitions & Contracts

[print friendly page]

Meperidine

Introduced as an analgesic in the 1930s, meperidine produces effects that are similar, but not identical, to morphine (shorter duration of action and reduced antitussive and antidiarrheal actions). Currently it is used for pre-anesthesia and the relief of moderate to severe pain, particularly in obstetrics and post-operative situations. Meperidine is available in tablets, syrups, and injectable forms under generic and brand name (Demerol®, Mepergan®, etc.) Schedule II preparations. Several analogues of meperidine have been clandestinely produced. During the clandestine synthesis of the analogue MPPP, a neurotoxic by-product (MPTP) was produced. A number of individuals who consumed the MPPP-MPTP preparation developed an irreversible Parkinsonian-like syndrome. It was later found that MPTP destroys the same neurons as those damaged in the Parkinsonian-like syndrome. It was later found that MPTP destroys the same neurons as those damaged in Parkinsons Disease.

Home USDOJ.GOV Privacy Policy Contact Us Site Map